2016
DOI: 10.1128/cvi.00444-16
|View full text |Cite
|
Sign up to set email alerts
|

Shigella Vaccine Development: Finding the Path of Least Resistance

Abstract: -16) report results from a phase I study of a parenterally administered monovalent O-polysaccharide "bioconjugate" directed against Shigella flexneri 2a. Ultimately, the goal is to develop a broad-spectrum Shigella vaccine to address this public health concern. A parenteral Shigella vaccine capable of eliciting protection in children of developing countries would be an important tool to reach this goal.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
15
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 16 publications
(16 citation statements)
references
References 49 publications
(43 reference statements)
1
15
0
Order By: Relevance
“…Shigellosis has been increasingly recognized worldwide and the need for better tools that improve testing of vaccines and other interventions is clearly evident. 14,16 This is the first study that describes a murine model of intestinal shigellosis mimicking the clinical outcomes that are commonly seen in children, including diarrhea and weight loss, with host zinc deficiency promoting more prolonged infection.…”
Section: Discussionmentioning
confidence: 99%
“…Shigellosis has been increasingly recognized worldwide and the need for better tools that improve testing of vaccines and other interventions is clearly evident. 14,16 This is the first study that describes a murine model of intestinal shigellosis mimicking the clinical outcomes that are commonly seen in children, including diarrhea and weight loss, with host zinc deficiency promoting more prolonged infection.…”
Section: Discussionmentioning
confidence: 99%
“…Preventing shigellosis remains more than ever a public health priority. [98][99][100] Indeed, as recently reviewed, 101 there is a growing appreciation for the role of vaccines in confronting the problem of antimicrobial resistance, which includes the alarming emergence of multi-drug resistant Shigella strains. 98…”
Section: Implications For Vaccine Developmentmentioning
confidence: 99%
“…Sf6TSP binds octasaccharide O‐antigen fragments with relatively low affinity due to a highly flexible reducing end pointing towards the enzyme's active site residues (Figure ). Sf6TSP therefore is a valuable target for generating mutants with increased O‐antigen affinity, as it can be used as a sensor for S. flexneri , an important diagnostic target pathogen that causes dysentery in infants . In solution, fluorescence amplitude changes upon glycan ligand binding were used to detect O‐polysaccharide binding via a cysteine coupled, environment‐sensitive fluorescent label in the Sf6TSP binding site .…”
Section: Introductionmentioning
confidence: 99%